Group 1 - Fortrea Holdings Inc. (NASDAQ:FTRE) is considered one of the best young stocks to buy and hold for three years, with recent price target adjustments from Mizuho and Truist indicating positive market sentiment [1][2][3] - Mizuho raised its price target on Fortrea to $15 from $13 while maintaining a Neutral rating, citing a sequential slowdown in healthcare utilization despite easier comparisons from the previous year [1] - Truist upgraded Fortrea from Hold to Buy, setting a new price target of $22, based on enhanced operational performance, emerging commercial strength, and improved profit margins under new leadership [2] - Evercore ISI upgraded Fortrea from In Line to Outperform, significantly raising its price target to $25 from $14, highlighting an accelerating biopharma cycle and improved execution as key drivers [3] Group 2 - Fortrea Holdings Inc. operates as a contract research organization, providing biopharmaceutical product and medical device development solutions to pharmaceutical, biotech, and medical device customers globally [4]
Mizuho Increases Fortrea (FTRE) PT to $15 Despite Signs of Peaking Healthcare Trends